EN DE
Watch THOMSON MEDICAL GROUP LIMITED for free: we tell you when fair value or trend changes.
Data-driven stock valuation

THOMSON MEDICAL GROUP LIMITED (A50) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of THOMSON MEDICAL GROUP LIMITED stock S$0.05, price S$0.05, upside +7.6%, quality 47 out of 100. Rating: fairly valued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SG · ISIN SG1M49904634

TM THOMSON MEDICAL GROUP LIMITED logo Thin data Nov 13, 2026

THOMSON MEDICAL GROUP LIMITED

A50 · SG

Company just good enough, but the stock is already about fairly priced and falling price: meets 1 of 3 rules.

Get notified free when this changes
Generates free cash flow 
Fair value 0.0484 SGD · Fairly valued 
Quality 47/100 
Mixed Growth (revenue 5y +11.8 %/yr in SGD) 
Revenue last quarter 17% below a year ago. 
Falling price (downtrend) 
Loss-making · -7.0% net margin (TTM) 
High debt 
Trails peers (2/11) 
Narrow moat 23/100 · thin data
Thin data 
⚠ Small free float
Watch THOMSON MEDICAL GROUP LIMITED for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.0898 SGD 0.0400 SGD Fair Value 0.0484 SGD Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range 0.0400 SGD – 0.0898 SGD · fair‑value band 0.0296 SGD – 0.0766 SGD · the 0.0450 SGD price screens below the 0.0484 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow THOMSON MEDICAL GROUP in your weekly email

Every Wednesday you see whether THOMSON MEDICAL GROUP is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Thomson Medical Group Limited, an investment holding company, provides healthcare services for women and children in Singapore, Malaysia, and Vietnam. The company owns and operates the Thomson Medical Centre, as well as a network of medical clinics and facilities.

Show moreShow less

It also offers urgent care services, such as basic resuscitation, ECG, vaccinations, IM/IV fluid and IV antibiotic administration, surgeries and procedures, wound care and stitching, and X-ray and basic laboratory tests; health screening services; services related to skin and aesthetics, and pain and rehab management; and herbal tea.

In addition, the company provides specialized services, such as women's health, children's health, fertility and family planning, eye health, general surgery, urology, preventive health and healthy ageing, diagnostic imaging, breast health, cardiology, respiratory medicine and critical care, endocrinology, dermatology, day surgery, surgical care, counselling and therapy, traditional Chinese medicine (TCM), as well as bone, joint, gynecological oncology, dentistry, and spine health.

It offers its products and services under the Thomson Women's Clinic, Thomson Fertility Centre, Thomson Paediatric Clinic, Thomson Specialists, Thomson Chinese Medicine, Thomson Surgical Centre, Thomson Dental Centre, Thomson Hospital Kota Damansara, TMC Fertility, TMC Care Pharmacy, FV Hospital, and FV Saigon Clinic brands.

Thomson Medical Group Limited was founded in 1979 and is based in Singapore.

Stock analysis

THOMSON MEDICAL GROUP LIMITED (A50) currently trades at 0.0450 SGD, while our model-based Fair Value estimate is 0.0484 SGD, so the stock looks roughly fairly valued today (gap 7.1%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.0500 SGD per share, and 1 of the 5 models we run sit above the 0.0450 SGD price.

Bear case: the DCF Models group reads lowest at 0.0350 SGD, and 4 of the 5 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.0296 SGD (bear) to 0.0766 SGD (bull), the price of 0.0450 SGD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

THOMSON MEDICAL GROUP LIMITED reported revenue of 420M SGD in FY2025 versus 334M SGD in FY2021, a compound +5.9%/yr. Reported net income was −29.7M SGD in FY2025.

Key figures

Market cap 1.2B SGD (≈ $924M) Small · P/S ratio 2.98 · Net margin −7.1% · Return on equity −5.2% · Return on assets (EBIT) 3.8% (5-year average) · Operating margin 11.1% · Revenue (TTM) 427M SGD · Revenue growth (YoY) −16.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 8%, A50 screens cheaper than that median.

Fair Value models

Bear 0.0296 SGD Fair Value 0.0484 SGD Bull 0.0766 SGD
Price 0.0450 SGD · Upside +7.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Growth DCF 0.0100 SGD 0.0500 SGD 0.1100 SGD 70
FCF DCF 0.0100 SGD 0.0400 SGD 0.1100 SGD 69
5Y Revenue Exit n/a n/a 0.0200 SGD 69
All 8 models by family
DCF Models
FCF DCF 0.0100 SGD 0.0400 SGD 0.1100 SGD 69
5Y Revenue Exit n/a n/a 0.0200 SGD 69
5Y EBITDA Exit n/a 0.0300 SGD 0.0700 SGD 65
10Y Revenue Exit n/a 0.0100 SGD 0.0300 SGD 64
10Y EBITDA Exit 0.0100 SGD 0.0400 SGD 0.1000 SGD 60
Multiples
EV/EBITDA n/a n/a 0.0100 SGD 62
Growth DCF
Growth DCF 0.0100 SGD 0.0500 SGD 0.1100 SGD 70
Rev-Margin DCF n/a n/a 0.0200 SGD 69

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 53
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 10
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 86
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Start year 2020 (pandemic). Over 10 years: +9.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+88.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
20.3% (2020) → 6.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Singapore: IMF forecast 2.0% a year to 2030, 1.7% from 2016 to 2025) that is about +21.1% a year for the price.

Watch A50, get fair value alerts →

Compare THOMSON MEDICAL GROUP LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +7.6% · Above median
Profitability
Return on assets −1.7% · Bottom 25%
Net margin (12 months) −7.0% · Bottom 25%
Operating margin (12 months) 11.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) −16.9% · Bottom 25%
Balance sheet
Debt / equity 2.04× · Highest 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 2.69× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 2.79× · Priciest 25%
Price / free cash flow (fiscal year) 23.3× · Pricier than median
EV/EBITDA 28.9× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)43 · sector 34
FUTURE (revenue growth)0 · sector 33
PAST (return on equity)0 · sector 32
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs A50
DaVita Inc DVA $174.56 $218.90 +25% vs A50
Aier Eye Hospital Group 300015 ¥8.99 ¥10.88 +21% vs A50
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs A50
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs A50
The Ensign Group ENSG $188.41 $140.09 −26% vs A50
Encompass Health Corporation EHC $140.99 $94.81 −33% vs A50
Fresenius SE FRE €53.86 €34.77 −35% vs A50
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,771 ₹5,234 −40% vs A50
Dr. Sulaiman Al Habib Medical Services Group 4013 211.40 SAR 109.45 SAR −48% vs A50

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

THOMSON MEDICAL GROUP LIMITED: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "THOMSON MEDICAL GROUP LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/A50

Frequently asked questions

Is THOMSON MEDICAL GROUP LIMITED (A50) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of 0.0484 SGD versus a price of 0.0450 SGD, about +8% upside (fairly valued).
What is the fair value of A50?
Our model-based fair value for THOMSON MEDICAL GROUP LIMITED is 0.0484 SGD (as of Nov 13, 2026), built from audited fundamentals. The current price: 0.0450 SGD.
What is the quality score of A50?
THOMSON MEDICAL GROUP LIMITED has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for THOMSON MEDICAL GROUP LIMITED (A50)?
Our model-based price target is the fair value of 0.0484 SGD (as of Nov 13, 2026) from 8 valuation models. Cautious scenario 0.0296 SGD, optimistic scenario 0.0766 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the THOMSON MEDICAL GROUP LIMITED stock forecast for 2026?
Our models put fair value at 0.0484 SGD, about +8% upside versus a price of 0.0450 SGD (fairly valued). Cautious scenario 0.0296 SGD, optimistic scenario 0.0766 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of THOMSON MEDICAL GROUP LIMITED (A50)?
THOMSON MEDICAL GROUP LIMITED reported trailing-twelve-month revenue of about 427M SGD (latest available figure, as of Nov 13, 2026).
What growth is priced into THOMSON MEDICAL GROUP LIMITED (A50)?
For today's price to be fair in a discounted-cash-flow model, THOMSON MEDICAL GROUP LIMITED would have to grow free cash flow by 23.5 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 11.8 % per year. As of Nov 13, 2026.
What discount rate (WACC) does the fair value of A50 use?
Our models discount THOMSON MEDICAL GROUP LIMITED at 9.6 %: a base by market capitalisation (small), damped by beta 0.28, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For THOMSON MEDICAL GROUP LIMITED that is +23.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has THOMSON MEDICAL GROUP LIMITED (A50) delivered so far?
Over the past 5 years revenue at THOMSON MEDICAL GROUP LIMITED grew 11.8 % a year. The price currently implies free-cash-flow growth of +23.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of THOMSON MEDICAL GROUP LIMITED (A50) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into THOMSON MEDICAL GROUP LIMITED (+23.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of THOMSON MEDICAL GROUP LIMITED (A50)?
The free-cash-flow yield on the price is 4.28 %: that much free cash flow THOMSON MEDICAL GROUP LIMITED produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of THOMSON MEDICAL GROUP LIMITED (A50)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For THOMSON MEDICAL GROUP LIMITED it is 0.0484 SGD per share (as of Nov 13, 2026), against a price of 0.0450 SGD. It is the blended result of 8 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is THOMSON MEDICAL GROUP LIMITED stock overvalued or undervalued in 2026?
As of Nov 13, 2026, A50 trades below its calculated fair value: price 0.0450 SGD, fair value 0.0484 SGD, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of A50?
No. The price is what the market pays today (0.0450 SGD); the fair value is what the company's own numbers justify (0.0484 SGD). For THOMSON MEDICAL GROUP LIMITED the two are 0.0034 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is THOMSON MEDICAL GROUP LIMITED worth?
The market values THOMSON MEDICAL GROUP LIMITED at about 1.2B SGD (market capitalisation, as of Nov 13, 2026). Per share that is 0.0450 SGD; our models calculate a fair value of 0.0484 SGD per share.
What do the bullish and bearish scenarios say about A50?
Our models span a range for THOMSON MEDICAL GROUP LIMITED: cautious scenario 0.0296 SGD, base 0.0484 SGD, optimistic 0.0766 SGD per share (as of Nov 13, 2026, price 0.0450 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of THOMSON MEDICAL GROUP LIMITED (A50)?
Balance-sheet figures for THOMSON MEDICAL GROUP LIMITED (as of Nov 13, 2026): return on equity −5.2%, debt of 2.04 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is A50 from its 52-week high?
THOMSON MEDICAL GROUP LIMITED trades at 0.0450 SGD, about 30% below its 52-week high of 0.0640 SGD and at the low of 0.0450 SGD (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0484 SGD is for.
Which stocks are comparable to THOMSON MEDICAL GROUP LIMITED?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is THOMSON MEDICAL GROUP LIMITED stock attractive at the current price?
The data as of Nov 13, 2026: price 0.0450 SGD, calculated fair value 0.0484 SGD (+8%), Quality Score 47/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of A50 calculated?
We run THOMSON MEDICAL GROUP LIMITED through 8 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of 0.0484 SGD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. THOMSON MEDICAL GROUP LIMITED currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of THOMSON MEDICAL GROUP LIMITED (A50)?
The closing price on Nov 16, 2026 was 0.0450 SGD. Our model-based fair value is 0.0484 SGD, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with THOMSON MEDICAL GROUP LIMITED right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (0.0296 SGD to 0.0766 SGD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of THOMSON MEDICAL GROUP LIMITED

How large is the market capitalisation of THOMSON MEDICAL GROUP LIMITED (A50)?
The market capitalisation of THOMSON MEDICAL GROUP LIMITED is 1.2B SGD (≈ $924M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of THOMSON MEDICAL GROUP LIMITED (A50)?
The price-to-sales ratio of THOMSON MEDICAL GROUP LIMITED is 2.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of THOMSON MEDICAL GROUP LIMITED (A50)?
The net margin of THOMSON MEDICAL GROUP LIMITED is −7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of THOMSON MEDICAL GROUP LIMITED (A50)?
The return on equity (ROE) of THOMSON MEDICAL GROUP LIMITED is −5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of THOMSON MEDICAL GROUP LIMITED (A50)?
On an EBIT basis the return on assets of THOMSON MEDICAL GROUP LIMITED is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of THOMSON MEDICAL GROUP LIMITED (A50)?
The operating margin of THOMSON MEDICAL GROUP LIMITED is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at THOMSON MEDICAL GROUP LIMITED (A50)?
Revenue at THOMSON MEDICAL GROUP LIMITED is down 16.9% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at THOMSON MEDICAL GROUP LIMITED (A50)?
Earnings per share at THOMSON MEDICAL GROUP LIMITED are down 3.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does THOMSON MEDICAL GROUP LIMITED (A50) carry?
The net debt of THOMSON MEDICAL GROUP LIMITED is 991M SGD (fiscal year 2025, ≈ 19.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch THOMSON MEDICAL GROUP LIMITED in the live analysis

One click puts THOMSON MEDICAL GROUP LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.